Bayer and Orion’s Nubeqa shows off strong overall survival benefit in castration-resistant prostate cancer

pharmafile | January 31, 2020 | News story | Medical Communications, Research and Development |  Bayer, orion, pharma 

Bayer and Finnish pharma firm Orion Corporation have announced positive new Phase 3 data for their jointly developed oral androgen receptor inhibitor (ARi) Nubeqa (darolutamide) in the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) in adult male patients.

The data showed that the drug, when combined with androgen deprivation therapy (ADT), demonstrated a “significant improvement” in overall survival benefit compared to placebo with ADT.

This benefit bolsters previous data supporting the combo’s efficacy in metastasis-free survival compared to the placebo combo. However, thus far, the combo has not produced mature data on its benefit in overall survival; these data as well as those on additional endpoints were confirmed to be in the pipeline to be presented at an upcoming scientific meeting.

The combo has already secured approval in the US, Brazil and Japan for this indication.

Matt Fellows